Drug Profile
Eravacycline - Tetraphase Pharmaceuticals
Alternative Names: TP-434; XERAVALatest Information Update: 29 Sep 2023
Price :
$50
*
At a glance
- Originator Paratek Pharmaceuticals
- Developer Everest Medicines; PAION; Tetraphase Pharmaceuticals
- Class Acetamides; Anti-infectives; Antibacterials; Antivirals; Fluorinated hydrocarbons; Pyrrolidines; Small molecules; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Intra-abdominal infections
- No development reported Bacterial infections; Respiratory tract infections
- Discontinued Urinary tract infections